Successful treatment of severe menorrhagia at menarche with recombinant factor VIIa in an adolescent girl with type III von Willebrand's disease

Gokcebay D. G., Culha V., Yarali N., Ozbek N. Y.

Blood Coagulation and Fibrinolysis, vol.29, no.5, pp.469-471, 2018 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 5
  • Publication Date: 2018
  • Doi Number: 10.1097/mbc.0000000000000739
  • Journal Name: Blood Coagulation and Fibrinolysis
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.469-471
  • Keywords: menorrhagia, recombinant factor VIIa, von Willebrand's disease
  • Ankara Yıldırım Beyazıt University Affiliated: No

Abstract

© 2018 Wolters Kluwer Health, Inc.Type III von Willebrand's disease (vWD) is an inherited bleeding disorder, which is frequently associated with menorrhagia in women. Treatment options include antifibrinolytics, desmopressin, von Willebrand factor/factor VIII concentrates and in intractable bleeding circumstances recombinant factor VIIa (rFVIIa). We present an adolescent case with type III vWD who had a menorrhagia at menarche that was refractory to the standard treatment and ultimately was treated with rFVIIa successfully.